AR106874A1 - Compuestos 1,3,4-tiadiazol y su uso en el tratamiento de cáncer - Google Patents
Compuestos 1,3,4-tiadiazol y su uso en el tratamiento de cáncerInfo
- Publication number
- AR106874A1 AR106874A1 ARP160103663A ARP160103663A AR106874A1 AR 106874 A1 AR106874 A1 AR 106874A1 AR P160103663 A ARP160103663 A AR P160103663A AR P160103663 A ARP160103663 A AR P160103663A AR 106874 A1 AR106874 A1 AR 106874A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydrogen
- methoxy
- tiadiazol
- compounds
- cancer treatment
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- -1 for example Proteins 0.000 abstract 9
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 abstract 2
- 102000009127 Glutaminase Human genes 0.000 abstract 1
- 108010073324 Glutaminase Proteins 0.000 abstract 1
- 102100025960 Glutaminase kidney isoform, mitochondrial Human genes 0.000 abstract 1
- 101000856990 Homo sapiens Glutaminase kidney isoform, mitochondrial Proteins 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
El compuesto de la fórmula (1) puede inhibir una glutaminasa, por ejemplo, GLS1. Reivindicación 1: Un compuesto caracterizado porque es de fórmula (1), o una sal del mismo aceptable farmacéuticamente, en donde: Q es 1,2,4-triazin-3-ilo, piridazin-3-ilo, 6-metilpiridazin-3-ilo o 6-fluoropiridazin-3-ilo; R¹ es hidrógeno, metoxi, trifluorometoxi, oxetan-3-ilo, 3-fluoroazetidin-1-ilo, 3-metoxiazetidin-1-ilo o 3,3-difluoroazetidin-1-ilo; R² es hidrógeno o fluoro; R³ es hidrógeno o metoxi; y R⁴ es metoxi, etoxi o metoximetilo; con la condición de que cuando R¹ es hidrógeno, metoxi o trifluorometoxi, R³ no es hidrógeno y/o R⁴ es metoximetilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562260789P | 2015-11-30 | 2015-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR106874A1 true AR106874A1 (es) | 2018-02-28 |
Family
ID=57485461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103663A AR106874A1 (es) | 2015-11-30 | 2016-11-30 | Compuestos 1,3,4-tiadiazol y su uso en el tratamiento de cáncer |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US10323028B2 (es) |
| EP (1) | EP3383873B1 (es) |
| JP (1) | JP6999550B2 (es) |
| KR (1) | KR20180083942A (es) |
| CN (1) | CN108349966B (es) |
| AR (1) | AR106874A1 (es) |
| AU (1) | AU2016363718B2 (es) |
| BR (1) | BR112018010806A2 (es) |
| CA (1) | CA3005495C (es) |
| CL (1) | CL2018001407A1 (es) |
| CO (1) | CO2018006928A2 (es) |
| EA (1) | EA201891241A1 (es) |
| ES (1) | ES2914333T3 (es) |
| IL (1) | IL259510A (es) |
| MX (1) | MX2018006532A (es) |
| NI (1) | NI201800064A (es) |
| PH (1) | PH12018501131A1 (es) |
| RU (1) | RU2018123714A (es) |
| SG (1) | SG11201803810XA (es) |
| SV (1) | SV2018005702A (es) |
| TN (1) | TN2018000127A1 (es) |
| TW (1) | TW201733587A (es) |
| WO (1) | WO2017093299A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201520959D0 (en) | 2015-11-27 | 2016-01-13 | Astrazeneca Ab And Cancer Res Technology Ltd | Bis-pyridazine compounds and their use in treating cancer |
| US10040789B2 (en) * | 2015-11-30 | 2018-08-07 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
| TW201733587A (zh) | 2015-11-30 | 2017-10-01 | 阿斯特捷利康公司 | 1,3,4-噻二唑化合物及其在治療癌症中之用途 |
| TW201730188A (zh) | 2015-11-30 | 2017-09-01 | 阿斯特捷利康公司 | 1,3,4-噻二唑化合物及其在治療癌症中之用途 |
| EP3640250B1 (en) * | 2017-06-13 | 2021-12-15 | Medshine Discovery Inc. | Compound as gls1 inhibitor |
| WO2020078350A1 (zh) | 2018-10-16 | 2020-04-23 | 南京明德新药研发有限公司 | 噻二唑衍生物及其作为gls1抑制剂的应用 |
| WO2025196446A1 (en) * | 2024-03-22 | 2025-09-25 | Sitryx Therapeutics Limited | Thiadiazoles as glutaminase 1 inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6451828B1 (en) * | 2000-08-10 | 2002-09-17 | Elan Pharmaceuticals, Inc. | Selective inhibition of glutaminase by bis-thiadiazoles |
| SI2782570T1 (sl) | 2011-11-21 | 2020-02-28 | Calithera Biosciences Inc. | Heterociklični inhibitorji glutaminaze |
| LT2920168T (lt) * | 2012-11-16 | 2021-10-25 | Calithera Biosciences, Inc. | Heterociklinis gliutaminazės inhibitorius |
| US9029531B2 (en) | 2012-11-22 | 2015-05-12 | Agios Pharmaceuticals, Inc. | Compounds and their methods of use |
| AU2015204210B2 (en) | 2014-01-06 | 2019-07-18 | Rhizen Pharmaceuticals Sa | Inhibitors of glutaminase |
| EP3116872A4 (en) * | 2014-03-14 | 2017-08-30 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
| GB201409624D0 (en) | 2014-05-30 | 2014-07-16 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
| GB201520959D0 (en) | 2015-11-27 | 2016-01-13 | Astrazeneca Ab And Cancer Res Technology Ltd | Bis-pyridazine compounds and their use in treating cancer |
| US10040789B2 (en) | 2015-11-30 | 2018-08-07 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
| TW201733587A (zh) | 2015-11-30 | 2017-10-01 | 阿斯特捷利康公司 | 1,3,4-噻二唑化合物及其在治療癌症中之用途 |
| TW201730188A (zh) * | 2015-11-30 | 2017-09-01 | 阿斯特捷利康公司 | 1,3,4-噻二唑化合物及其在治療癌症中之用途 |
-
2016
- 2016-11-29 TW TW105139337A patent/TW201733587A/zh unknown
- 2016-11-29 US US15/363,030 patent/US10323028B2/en active Active
- 2016-11-30 BR BR112018010806A patent/BR112018010806A2/pt not_active Application Discontinuation
- 2016-11-30 AR ARP160103663A patent/AR106874A1/es unknown
- 2016-11-30 MX MX2018006532A patent/MX2018006532A/es unknown
- 2016-11-30 KR KR1020187018472A patent/KR20180083942A/ko not_active Withdrawn
- 2016-11-30 WO PCT/EP2016/079250 patent/WO2017093299A1/en not_active Ceased
- 2016-11-30 RU RU2018123714A patent/RU2018123714A/ru not_active Application Discontinuation
- 2016-11-30 AU AU2016363718A patent/AU2016363718B2/en active Active
- 2016-11-30 CA CA3005495A patent/CA3005495C/en active Active
- 2016-11-30 ES ES16806028T patent/ES2914333T3/es active Active
- 2016-11-30 EA EA201891241A patent/EA201891241A1/ru unknown
- 2016-11-30 TN TNP/2018/000127A patent/TN2018000127A1/en unknown
- 2016-11-30 CN CN201680067245.3A patent/CN108349966B/zh active Active
- 2016-11-30 JP JP2018526716A patent/JP6999550B2/ja active Active
- 2016-11-30 SG SG11201803810XA patent/SG11201803810XA/en unknown
- 2016-11-30 EP EP16806028.3A patent/EP3383873B1/en active Active
-
2018
- 2018-05-22 IL IL259510A patent/IL259510A/en unknown
- 2018-05-24 CL CL2018001407A patent/CL2018001407A1/es unknown
- 2018-05-29 SV SV2018005702A patent/SV2018005702A/es unknown
- 2018-05-29 PH PH12018501131A patent/PH12018501131A1/en unknown
- 2018-05-29 NI NI201800064A patent/NI201800064A/es unknown
- 2018-06-29 CO CONC2018/0006928A patent/CO2018006928A2/es unknown
-
2019
- 2019-05-03 US US16/402,825 patent/US10981904B2/en active Active
-
2021
- 2021-04-15 US US17/231,164 patent/US11753405B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SV2018005702A (es) | 2018-11-27 |
| JP2018535986A (ja) | 2018-12-06 |
| SG11201803810XA (en) | 2018-06-28 |
| NI201800064A (es) | 2018-10-18 |
| US20210246131A1 (en) | 2021-08-12 |
| CA3005495C (en) | 2023-12-12 |
| CL2018001407A1 (es) | 2018-10-12 |
| CA3005495A1 (en) | 2017-06-08 |
| WO2017093299A1 (en) | 2017-06-08 |
| RU2018123714A (ru) | 2020-01-09 |
| PH12018501131A1 (en) | 2019-01-21 |
| JP6999550B2 (ja) | 2022-02-10 |
| TN2018000127A1 (en) | 2019-10-04 |
| US20190389853A1 (en) | 2019-12-26 |
| KR20180083942A (ko) | 2018-07-23 |
| MX2018006532A (es) | 2019-05-15 |
| ES2914333T3 (es) | 2022-06-09 |
| US20170152255A1 (en) | 2017-06-01 |
| CN108349966A (zh) | 2018-07-31 |
| US11753405B2 (en) | 2023-09-12 |
| AU2016363718A1 (en) | 2018-07-12 |
| CO2018006928A2 (es) | 2018-10-10 |
| BR112018010806A2 (pt) | 2018-11-27 |
| TW201733587A (zh) | 2017-10-01 |
| EP3383873B1 (en) | 2022-03-09 |
| IL259510A (en) | 2018-07-31 |
| US10323028B2 (en) | 2019-06-18 |
| EA201891241A1 (ru) | 2019-01-31 |
| EP3383873A1 (en) | 2018-10-10 |
| US10981904B2 (en) | 2021-04-20 |
| AU2016363718B2 (en) | 2019-11-14 |
| CN108349966B (zh) | 2022-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR106874A1 (es) | Compuestos 1,3,4-tiadiazol y su uso en el tratamiento de cáncer | |
| AR110400A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| CL2019003126A1 (es) | Métodos de tratamiento mediante el uso de un compuesto inhibidor de jak. | |
| NI202000092A (es) | Compuestos | |
| MX384905B (es) | Degradadores de proteínas de bromodominio y dominioextraterminal (bet). | |
| NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
| TN2019000210A1 (en) | Antitumoral compounds | |
| MX2019009114A (es) | Sal de hemisulfato de nucleotido para el tratamiento del virus de hepatitis c. | |
| CL2017002456A1 (es) | Composiciones y métodos para el tratamiento de la anemia. | |
| MX369649B (es) | Analogos de dioxolano de uridina para el tratamiento del cancer. | |
| AR103680A1 (es) | Inhibidores selectivos de bace1 | |
| NI201800065A (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento de cáncer | |
| AR112102A1 (es) | Tinostamustina para utilizar en el tratamiento de cáncer de ovario | |
| MX2018014080A (es) | Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia. | |
| EA201891239A1 (ru) | 1,3,4-тиадиазольные соединения и их применение в лечении рака | |
| AR106849A1 (es) | Compuestos de bis-piridazina y su uso en el tratamiento del cáncer | |
| MX2018014081A (es) | Uso de compuesto de carbamato para prevenir o tratar neuralgia trigeminal. | |
| MX2018007796A (es) | Compuestos de fenilimidazol. | |
| AR115865A2 (es) | Compuestos terapéuticos | |
| AR111017A1 (es) | Sal hemisulfato de un compuesto nucleotídico para el tratamiento del virus de la hepatitis c | |
| AR105924A1 (es) | Compuestos terapéuticos y síntesis | |
| EA201992372A1 (ru) | Макроциклическое соединение и его применения | |
| UA89726U (ru) | Применение n,n'-(этан-1,2-диил)бис(хинолин-2-карбоксамида) как средства с гипогликемическим действием |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |